Patent portfolios and Intellectual Property are a core component of any biotechnology company and a necessity when building a competitive advantage. We are extremely pleased with our strong portfolio of IP assets that we have assembled in the the co-stimulatory CAR-T Gamma Delta T-cell space," said Bryan Kobel, CEO of TC BioPharm. "These assets form the foundation for our ability to strengthen our product pipeline, and enhance our position as a leader in the field of Gamma Delta-T based immuno-oncology. Going forward we intend to continue to advance our global clinical development and commercialization strategy supported by our strong intellectual property estate."
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful”
Warren Buffett
Market Data 
Markets 
AI
